Point of Care Diagnostic Testing Market Research

The report “Point of Care Diagnostic Testing World Markets″ by TriMark Publications, LLC is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with Point of Care Diagnostic Testing World Markets in subject line and your contact details to purchase this report or get your questions answered.

Point of care testing (POCT) enables rapid diagnostic tests to be performed while the patient is at the point of care facility where results can be obtained immediately, rather than waiting hours or even days for outside lab results to arrive. Point of care testing covers: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing, rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing and cholesterol screening. This TriMark Publications report describes latest developments in the point of care testing market segment. It examines clinical instruments, devices and reagents and supplies as utilized in near-patient environments like hospital emergency rooms, critical care units, clinics and doctor’s offices.

Get sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=58693 .

The study defines the dollar volume of point of care sales and makes five year projections–both in the U.S. and worldwide–including Europe, Asia and Latin America. It also examines in detail the point of care sector for 25 individual country markets. A detailed summary of all important instruments in each clinical market is provided with emphasis on newly introduced products. Moreover, parallel areas where rapid detection is important using hand-held devices such as rapid detection of food pathogens and infectious diseases (MRSA, herpes simplex, avian flu, West Nile virus and typhoid) are discussed.

Purchase a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=58693 .

Growth moderators and developing trends in point of care applications, as well as technology platform innovations and connectivity questions are examined in detail. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the point of care market in the U.S. and worldwide. Each company is discussed in depth, with a section on its history, product lines, business and marketing analysis, and a subjective commentary of the company’s market position. Detailed tables and charts with sales forecasts and market data are also included

Complete report available @ http://www.rnrmarketresearch.com/point-of-care-diagnostic-testing-world-markets-market-report.html .

Table of Contents

·         Overview

·         Overview of Diagnostic Testing Point of Care Markets

·         Summary Analysis of the Global POCT Market: Value, Growth Rates and Market Share

·         Analysis of the U.S. POCT Market: Value, Growth Rates and Market Share

·         Analysis of the European POCT Market: Value, Growth Rates and Market Shares

·         Analysis of the POCT Markets for Japan, China and India: Value, Growth Rates and Market Share

·         Analysis of the Rest of World (ROW) POCT Market: Value, Growth Rates and Market Share

·         Review of the Market Segments, Reagents and Equipment

·         POCT: Growth Regulators

·         Business Trends in the POC Sector

·         Technology Platform Innovations in POCT

·         Data Management and Connectivity

·         Corporate Profiles

·         POCT Sector Trends and Forecasts

·         New Entrants to the Point of Care Market

Browse Blood Supply, Tissue Banking, Transplantation Industry Reports @ http://www.rnrmarketresearch.com/blood-glucose-testing-and-diabetes-management-market-report.html .

Blood Glucose Testing & Diabetes Management Market Size, Growth, Share & Competitors

The report “Blood Glucose Testing and Diabetes Management″ by TriMark Publications, LLC is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with Blood Glucose Testing and Diabetes Management in subject line and your contact details to purchase this report or get your questions answered.

There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease–sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes–the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes, particularly Type 2 diabetes, among adults across the world. As such, the global market for blood glucose testing products is undergoing a significant transition driven by the advent of new analytical technologies and developments in diabetes treatment.

Get sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=58685 .

Although the blood glucose testing segment of the in vitro diagnostics (IVD) industry is mature, certain segments of the market, such as home testing devices for diabetes management, will exhibit strong growth. What’s more, non-invasive testing now represents a major new area for the application of IVD testing. Additionally, direct access testing–or over-the-counter testing, which allows consumers to order tests themselves without visiting a doctor–has emerged as a strong force in the blood glucose testing segment. The purpose of this TriMark Publications report is to describe the specific market segments for blood glucose testing and diabetes management. This study reviews all of the generally-accepted clinical analytical methods that are currently in use today for measuring serum or plasma or whole-blood glucose concentrations.

Purchase a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=58685 .

Moreover, it examines clinical measurement devices, reagents and supplies as utilized in hospitals, clinics, doctor’s offices and at-home care locations. The report has made a survey of selected companies marketing, manufacturing or developing various blood glucose testing and diabetes management supplies throughout the world. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company’s market position. Detailed tables and charts with sales forecasts and market share data are also included

Complete report available @ http://www.rnrmarketresearch.com/blood-glucose-testing-and-diabetes-management-market-report.html .

Table of Contents

·         Overview

·         Diabetes

·         Market Analysis: Size, Growth, Share and Competitors

·         Glucose Diagnostic and Monitoring Recommendations

·         Glucose Testing Technology Platforms and Consumable Products

·         Glucose Testing Devices on the Market

·         Business Trends in Glucose Testing

·         Technology Trends

·         Company Profiles

Browse Blood Supply, Tissue Banking, Transplantation Industry Reports @ http://www.rnrmarketresearch.com/blood-glucose-testing-and-diabetes-management-market-report.html .

Epigenetic Modification Screening Industry 2014

The report “Epigenetic Modification Screening Trends 2014″ by HTStec Ltd is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with Epigenetic Modification Screening Trends 2014 in subject line and your contact details to purchase this report or get your questions answered.

"Epigenetic Modification Screening Trends 2014" market report summarizes the results of HTStec’s 3rd industry-wide global web-based benchmarking survey on epigenetic modification screening carried out in May 2014. The main questionnaire consisted of 29 multi-choice questions and 2 open-ended questions. In addition, there were 9 questions related solely to survey demographics. The survey collected 91 validated responses, of these 65% provided comprehensive input. Survey responses were geographically split: 65% North America; 25% Europe; 7% Asia (excluding Japan); 2% Japan; and 1% China. Survey respondents were drawn from persons or groups performing epigenetic modification screening assays or planning future investigation in this area.

Get sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=183512 .

The survey looked at the following aspects of epigenetic modification screening, as practiced today (2014) and in some cases as predicted for the future (2016):

·         Opinion on the current status of epigenetic targets

·         Key diseases/therapeutic area(s) investigating epigenetic modification

·         Level of priority for epigenetic modification research

·         Epigenetic modification classes of greatest interest, and where respondents have investigated assay feasibility or already performed in house or outsourced testing

·         Main source/origin of epigenetic proteins used

·         Stages in the drug discovery process using biochemical assays and/or cellular assays for epigenetic modification

·         Epigenetic modifications proteins with adequate biochemical and cellular assays

·         Preferred biochemical and cellular assay format/detection technologies for internal work and when outsourcing testing against epigenetic modifications proteins;

·         Substrates most commonly used for epigenetic assays

·         The challenges of assay development of epigenetic modification proteins; new tools required to drive the investigation of epigenetic modification assays

·         What limits epigenetic modification screening

·         Aspects of epigenetic modification drug discovery that are most limiting today

·         Where the situation concerning the main limitations of epigenetic modification screening assays has improved in the past 2 years

·         Number of FTE devoted to epigenetic modification research and different targets supported

·         Number of epigenetic modification primary screens and wells per screen

·         Approach to the primary screening (HTS) of epigenetic targets

·         Proportion of epigenetic primary screens that are biochemical assays

·         In house epigenetic modification assay reagent budget and breakdown into components purchased

·         Main suppliers of reagents and tools used to assay epigenetic modifications in house

·         Average material cost per well of epigenetic modification screening assays

·         Interest in outsourcing epigenetic modification research

·         Proportion of epigenetic modification testing outsourced and number of wells outsourced

·         Budget for outsourcing epigenetic modification assays and services

·         Preferred fee-for-service providers for outsourced epigenetic modification profiling assays

·         Unmet needs in epigenetic enzyme assays and screening today

Purchase a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=183512 .

A median of 21-30% of all epigenetic primary screens were enzyme/biochemical assays in 2014. A median budget of $5K-$25K/lab was allocated for epigenetic enzyme assay reagents in 2014. A bottom-up model developed around respondent’s annual budget for epigenetic modification assay reagents estimated the global market to be around $52M in 2014. The greatest share of this market was allocated to assay specific probes and biochemical assay kits. The most used commercial sources of reagents and tools for in house epigenetic modification assays were Life Technologies, Abcam and Sigma Aldrich. The median cost per single well for epigenetic modification assays undertaken in house was $0.75-$1.0 for biochemical assays versus $1-$2 for cellular assays. Profiling against panels of epigenetic targets using biochemical or cellular assays were the aspects of epigenetic modification research most respondents were interested to outsource. The median % of epigenetic modification primary screening outsourced in 2014 was ‘none’. The median % of epigenetic modification profiling outsourced in 2014 was <10%. The median total number of single wells outsourced to a fee-for-service provider for epigenetic primary screening and profiling was <100 wells in 2014.

A bottom-up model developed around respondent’s annual budget for outsourced epigenetic modification testing and services estimated the global market to be around $4M in 2014. The preferred fee-for-service providers of epigenetic modification profiling assay services were Life Technologies, Cisbio and Eurofins. The full report provides the data, details of the breakdown of the responses for each question, its segmentation and the estimates for the future (2016). It also highlights some interesting differences, particularly between Pharma versus the other survey groups.

Complete report available @ http://www.rnrmarketresearch.com/epigenetic-modification-screening-trends-2014-market-report.html .

Browse Drug Discovery Industry Reports @ http://www.rnrmarketresearch.com/reports/life-sciences/biotechnology/drug-discovery .